Clostridium difficile: new therapeutic options

Research output: Contribution to journalReview articlepeer-review

Abstract

Clostridium difficile disease is the major, known cause of nosocomial diarrhea and is an emerging cause of community-associated diarrhea. Recent outbreaks due to a strain of apparent increased virulence, BI/NAP1, and recognition of increasing metronidazole treatment failures as well as the morbidity associated with recurrent C. difficile disease have begun to spur studies to develop new therapies for C. difficile disease. Nitazoxanide, tolevamer, ramoplanin, and rifaximin are key agents being evaluated as new therapies for C. difficile disease. For now, vancomycin or metronidazole combined with discontinuation of antibiotics, when feasible, and expert infection control remain the mainstays of C. difficile disease management.

Original languageEnglish (US)
Pages (from-to)455-458
Number of pages4
JournalCurrent Opinion in Pharmacology
Volume7
Issue number5
DOIs
StatePublished - Oct 1 2007

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Clostridium difficile: new therapeutic options'. Together they form a unique fingerprint.

Cite this